• Independant law firm

    Independant law firm

  • in intellectual property

    in intellectual property

  • with international scope

    with international scope

  • July 2022

    Cabinet Barny advised Enterome on the conclusion of a collaboration agreement with Nestlé Health Science.

    Click here for more information.

    Read more

  • June 2022

    Cabinet Barny advised Coave Therapeutics on the conclusion of a collaboration agreement with ABL.

    Click here for more information.

    Read more

  • September 2021

    Cabinet Barny advised Coave Therapeutics on the conclusion of an exclusive license agreement with Théa Open Innovation.

    Click here for more information.

    Read more

  • February 2020

    Cabinet Barny advised Neurochlore on the conclusion of an exclusive license agreement with Hyundai for the development and commercialization of ASD treatment

    Read more

  • October 2018

    Cabinet Barny advised Enterome on the conclusion of a global licensing, co-development and co-promotion agreement with Takeda for the treatment of Crohn’s disease.

    Enterome will receive an upfront payment of $50 million and a commitment from Takeda to make a future equity investment in the Company. Enterome is also eligible to receive up to $640 million for achieving specified clinical development, regulatory and commercial milestones with Enterome's drug candidate EB8018.

    Click here for more information.

    Read more

  • April 2018

    Cabinet Barny advised Domain Therapeutics on the assignment of its intellectual property rights towards Foliglurax in the course of Lundbeck's acquisition of Prexton Therapeutics.

    Read more

  • May 2017

    Cabinet Barny advised ILTOO PHARMA on the conclusion of a license option agreement with Servier for the clinical development and commercialization of the ILT-101 drug candidate for the treatment of autoimmune diseases.

    Click here for more information.

    Read more

  • April 2017

    Cabinet Barny advised Domain Therapeutics on the conclusion of a collaboration agreement with Pfizer.

     

    Click here for more information.

    Read more

  • March 2017

    Cabinet Barny advised Neurochlore on the conclusion of an exclusive license agreement with Servier for the development and commercialization of bumetanide in the field of autism in children in Europe.

    Read more

  • November 2016

    Cabinet Barny advised Enterome on the conclusion of a collaboration agreement with Bristol-Myers Squibb in the field of Immuno-Oncology, focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules.

     

    Click here for more information.

    Read more

  • October 2016

    Cabinet Barny advised Domain Therapeutics on the creation with Medicxi of Mavalon Therapeutics, a company focused on stopping the progression of Parkinson's disease.

     

    Click here for more information.

    Read more

  • September 2016

    Cabinet Barny advised Domain Therapeutics on the conclusion of a second licensing and partnership agreement on GPCR biosensor technology with Université de Montréal, the Institute for Research in Immunology and Cancer – Commercialization of Research and McGill University.

     

    Click here for more information.

    Read more

  • JUNE 2016

    Cabinet Barny advised Meiogenix on the conclusion of a collaboration agreement with Lesaffre in the field of industrial yeast strains.

    Click here for more information.

    Read more

  • APRIL 2016

    Cabinet Barny advised Meiogenix on the conclusion of a licence agreement with Bayer, where Meiogenix has granted Bayer a licence on its StiX proprietary technology, in the field of genetic technologies.

    Click here for more information.

    Read more

  • March 2016

    Cabinet Barny advised Peptimimesis on the conclusion of a research partnership agreement with Ipsen in the field of oncology.

    Read more

    Logo - Barny Avocats
    52, avenue des Vosges
    67000 Strasbourg

    Tél. +33 (0)3 88 36 34 39
    Fax. +33 (0)3 88 35 24 71